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ABSTRACT: Many xenobiotic compounds exert their actions through the release of free 
radicals and related oxidants [1,2], bringing about unwanted biological effects [3]. Indeed, 
oxidative events may play a significant role in tobacco toxicity from cigarette smoke. Here, 
we demonstrate the direct in vitro release of the free radical nitric oxide (
•NO) from extracts 
and components of smokeless tobacco, including nicotine, nitrosonornicotine (NNN) and 4-
(methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in phosphate buffered saline and 
human saliva using electron spin resonance and chemiluminescence detection. Our findings 
suggest that tobacco xenobiotics represent as yet unrecognized sources of 
•NO in the body. 
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INTRODUCTION 
 
Whether generated intracellularly, or exogenously 
delivered, the diatomic free radical nitric oxide (
•NO) is 
rapidly disseminated throughout the body, affecting key 
biological processes. Supra-physiologic 
•NO concentra-
tions favor the formation of a potent biological oxidant; 
peroxynitrite (ONOO
-), the reaction product of 
•NO and 
the oxygen-centered free radical, superoxide, O2
•− [4]. 
Numerous cytotoxic lesions have been attributed to 
ONOO
-, including lipid peroxidation, protein thiol oxi-
dation, inhibition of Fe-S enzyme systems, and oxida-
tive DNA lesions such as strand breaks and base modi-
fications, to name some [4-6].   
Of the over 30 carcinogens found in tobacco, the 
nitrosamine compounds, nitrosonornicotine (NNN) and 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 
are thought to be the major contributors to the carcino-
genic activity of nicotine and tobacco [7,8]. NNN and 
NNK are formed during the curing, aging, and fermen-
tation of tobacco, as well as during nicotine metabo-
lism. Already, 
•NO generation has been demonstrated 
in cigarette smoke [9]. The structural similarities be-
tween NNN and NNK, and other known therapeutic 
and experimental 
•NO-releasing compounds suggest 
that these nitrosamines may be novel 
•NO-releasing 
agents in tobacco [10,11]. Indeed, NNK has been shown 
to generate DNA strand breaks, as well as induce the 
formation of DNA adducts, including methylated DNA 
[12,13].  
Here, we demonstrate, using both direct and indi-
rect methods, the in vitro release of 
•NO from extracts 
and components of smokeless tobacco, including nico-
tine, and the nitrosamine metabolites of tobacco, nitroso-
nornicotine (NNN) and 4-(methyl-N-nitrosamino)-1-(3-
pyridyl)-1-butanone (NNK). 
 
MATERIALS AND METHODS 
 
Tobacco xenobiotic preparations 
Experiments were conducted in phosphate-buf-
fered saline (PBS) at pH 7.4 or unstimulated human 
saliva obtained from healthy, non-users of tobacco, 
without clinical evidence of periodontal disease. We 
estimated the mass of a “pinch” of smokeless tobacco 
to be approximately 2.2 g, and suspended this 
(Copenhagen
® brand, National Tobacco Co., Ltd., 
Pointe Claire, QB) in 4.4 mL of PBS or saliva. The 
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Table 1. Chemiluminescent detection of 
•NO 
   Total 
•NO observed 
  in PBS (pH 7.4)  in human saliva 
PBS  5 ± 1 µM
a - 
Whole human saliva (WHS)  -  38 ± 17 µM
a 
Smokeless tobacco (ST )  1100 ± 50 µM
a 
2.53 ± 0.10 µmol/g ST 
1380 ± 80 µM
a 
2.76 ± 0.16 µmol/g ST 
Nicotine  < 0.02 µM
b  150 ± 12 µM
a 
2.81 ± 0.23 nmol/mg nicotine 
Nitrosonornicotine (NNN)  < 0.02 µM
b  121 ± 6 µM
a 
5.90 ± 0.30 nmol/mg NNN 
4-(Methyl-N-nitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) 
< 0.02 µM
b  113 ± 5 µM
a 
5.45 ± 0.25 nmol/mg NNK 
aThis is the apparent concentration of 
•NO present as NO2
− in the aqueous incubation injected into the Sievers NOA 
analyzer. 
bThe limit of detection with our experimental conditions. 
amount of nicotine in this preparation has been deter-
mined previously to be 12 ± 0.7 mg per g tobacco [8]. 
Therefore, 26.4 mg of nicotine (Sigma Chemical Co., St 
Louis, MO) was used for the assays. Ten mg of NNN 
and NNK (Midwest Research Institute, St. Louis, MO) 
was used for 
•NO determinations. Each of these pre-
pared solutions was purged with argon gas, and incu-
bated at 37ºC for 20 min in an air-tight container before 
being assayed for 
•NO. 
 
EPR spin trapping 
Each xenobiotic preparation was incubated with a 
10 mM solution of the iron (II)/N-methyl-D-glucamine 
dithiocarbamate, Fe
2+(MGD)2, spin trap at 37ºC for 20 
min so that the final concentration of the spin trap was 
1 mM [14]. Each 500 µL solution was then quickly 
transferred to an argon-purged flat cell, and EPR spec-
tra were collected with a Bruker (Billerica, MA, USA) 
X-band EMX spectrometer operating at 9.75 GHz, re-
ceiver gain of 2 x 10
4, modulation amplitude of 1 G, 
sweep time of 83 s, and a field center of 3418 G for 
•NO-Fe
2+(MGD)2. Each spectrum represents the signal-
averaged sum of 15 acquisitions.  
 
Chemiluminescent detection 
Fifty µL of each xenobiotic solution was injected 
into a Sievers 280 Nitric Oxide Analyzer (Boulder, CO, 
USA) containing a reducing agent, KI, potassium io-
dide (5.9 mM) in glacial acetic acid [14]. Standardiza-
tion was accomplished by injecting various concentra-
tions of a standard solution of NaNO2 into the same 
reducing environment. Samples were run in triplicate. 
 
RESULTS AND DISCUSSION 
 
Electron paramagnetic resonance (EPR) spin 
trapping was used to identify 
•NO release from tobacco 
xenobiotics. The EPR-silent 
•NO spin trap iron (II)/N-
methyl-D-glucamine dithiocarbamate, Fe
2+(MGD)2, 
coordinates the free 
•NO radical in aqueous solution, 
forming a stable, EPR-visible spin adduct, 
•NO-
Fe
2+(MGD)2. This species yields a characteristic three-
line EPR spectrum with an inter-peak hyperfine split-
ting value, aN, of 12.4 G and an isotropic nuclear g 
value, giso, of 2.04, both of which are characteristic of 
trapped 
•NO [14] (Figure 1). We observed unstimulated 
•NO release from smokeless tobacco extract and NNN, 
and weak release from NNK in PBS. Free 
•NO was not 
detected from pure nicotine under these conditions. 
However, given its chemical structure, we would not 
expect to observe an EPR signal from nicotine. When 
these experiments were performed in human saliva 
under identical conditions, we observed substantially 
stronger EPR signals. We believe this increased signal 
strength to be derived, in part, from the reduction of 
salivary NO2
− by cytochrome cd1 nitrite reductase 
found in some salivary bacteria [15,16]. Under these 
conditions, we observed a substantial EPR signal from 
nicotine in human saliva. The intensity of this sig- 
nal suggests there to be substantial biotransformation of  
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Figure 1. EPR spectra of the 
•NO-Fe(MGD)2 spin adduct formed from the release of 
•NO from tobacco xenobiotics 
in phosphate buffered-saline at pH 7.4 (left column) and human saliva (right column). The hyperfine splitting value, 
aN, of these spectra is 12.4 G and the isotropic nuclear g value, giso, is 2.04. (a) 500 µL phosphate buffered saline 
(left column) or whole human saliva (right column); (b) 500 µL of a 1:1 w/v extract of smokeless tobacco; (c) 3.48 
M (26.7 µG) nicotine; (d) 1.1 M (10 mg) nitrosonornicotine (NNN); and (e) 1.0 M (10 mg) 4-(methyl-N-
nitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Each spectrum represents 15 summed signal acquisitions acquired
using a receiver gain of 2 x 10
4 and modulation amplitude of 1 G. The ordinate scale is ± 1 x 10
3 arbitrary units for 
all spectra in whole human saliva. 
  in PBS (pH 7.4)  in human saliva 
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nicotine, facilitating the release of 
•NO. These results 
suggest that nicotine-derived 
•NO may substantially 
contribute to the systemic 
•NO load to an extent not 
previously recognized. 
As EPR is only semi-quantifiable, we used a 
chemiluminescence technique to determine 
•NO con-
centrations derived from smokeless tobacco xenobiot-
ics. This technique, however, detects only the end-
product of 
•NO oxidation, namely NO2
-. The use of this 
technique together with EPR spin trapping is consid-
ered complementary [14]. The results of these experi-
ments are summarized in Table 1. Briefly, phosphate 
buffered saline and human saliva generate 5 ± 1 µM 
and 38 ± 17 µM 
•NO, respectively, while extracts of 
smokeless tobacco in these fluids produced 1100 ± 50 
µM 
•NO (2.53 ± 0.10 mmol 
•NO/g ST) and 1380 ± 80 
µM (2.76 ± 0.16 mmol 
•NO/g ST), respectively. The 
similarity of these results may reflect the high inherent 
NO2
- content of processed smokeless tobacco [5]. We 
were unable to detect 
•NO from nicotine, NNN and 
NNK in PBS; the concentrations of NNN- and NNK-
derived 
•NO were likely below the detection threshold 
of the technique (0.2 µM). When nicotine, NNN and 
NNK were incubated in human saliva, we detected mi-
cromolar (or nanomole quantities per milligram xeno-
biotic) of 
•NO: 150 µM ± 12 from nicotine (2.81 ± 0.23 
nmol/mg nicotine), 121 ± 6 µM from NNN (5.90 ± 0.30 
nmol/mg NNN) and 113 ± 5 µM from NNK (5.45 ± 
0.25 nmol/mg NNK), respectively. As nicotine and the 
nitrosamine metabolites are found in milligram and 
microgram quantities per gram of smokeless tobacco, 
the putative 
•NO load derived from these compounds is 
substantial. Moreover, the importance of saliva in 
•NO 
release from these compounds is notable.  
Although others have reported free radical, and in 
particular, O2
•- production in cells exposed to smoke-
less tobacco and nicotine [17-19], none identified free 
radical release directly from smokeless tobacco xenobi-
otics. Tobacco xenobiotics represent as yet unrecog-
nized sources of 
•NO in the body. Indeed tobacco-
derived 
•NO may have widespread biological implica-
tions for tobacco users. Our results also lead us to 
speculate that 
•NO and nitrosative events may play a 
role in tobacco toxicity in the oral cavity and aerodiges-
tive tract.  
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